Phreesia, Inc.
HealthcareNYSE:PHR · New York Stock Exchange
+$0.01 today
Vol 0.70M · Avg 2.02M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Earnings Waterfall
Revenue to Net Income
Key Ratios
Analysis
$495.6M of revenue converted into $9.2M of net income for the selected period. Gross margin is 65.9% and net margin is 1.8%, showing how much revenue survives after costs and taxes. EPS is $0.15, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $480.6M +14.5% | $419.8M +17.8% | $356.3M +26.8% | $280.9M +31.7% | $213.2M | $1.0B | $809.6M | $921.6M |
| Cost of Revenue | $154.1M +14.2% | $134.9M +8.8% | $124.0M +13.5% | $109.3M +34.3% | $81.4M | $344.8M | $725.6M | $804.0M |
| Gross Profit | $326.5M +14.6% | $284.9M +22.6% | $232.3M +35.3% | $171.6M +30.2% | $131.8M | $10.3B | $8.9B | $7.6B |
| Gross Margin | 67.9% +0.1pp | 67.9% +2.7pp | 65.2% +4.1pp | 61.1% -0.7pp | 61.8% | 45.5% | 9.8% | 28.9% |
| Research & Development | $121.5M +3.5% | $117.4M +4.5% | $112.3M +23.1% | $91.2M +74.6% | $52.3M | $378.4M | $983.2M | $1.3B |
| Selling, General & Admin | $180.1M -8.9% | $197.7M -12.9% | $226.9M -2.0% | $231.6M +32.3% | $175.1M | $1.4B | $620.6M | $923.0M |
| Operating Expenses | $333.1M -2.9% | $343.0M -7.0% | $368.8M +5.9% | $348.2M +40.0% | $248.7M | $3.6B | $5.3B | $7.0B |
| Depreciation & Amortization | $31.5M +12.8% | $27.9M -8.7% | $30.5M +6.2% | $28.8M +17.3% | $24.5M | $1.2B | $374.2M | $1.2B |
| EBITDA | $29.5M +215.2% | -$25.6M +75.2% | -$102.9M +29.2% | -$145.5M -57.6% | -$92.3M | $12.6B | -$15.2B | $6.8B |
| EBITDA Margin | 6.1% +12.2pp | -6.1% +22.8pp | -28.9% +22.9pp | -51.8% -8.5pp | -43.3% | 10.0% | 5.6% | 46.3% |
| Operating Income | -$6.6M +88.6% | -$58.1M +57.4% | -$136.5M +22.7% | -$176.6M -51.1% | -$116.8M | $10.6B | $12.3B | $14.0B |
| Operating Margin | -1.4% +12.5pp | -13.8% +24.5pp | -38.3% +24.5pp | -62.9% -8.1pp | -54.8% | 18.7% | 16.6% | 24.1% |
| Interest Income | $2.2M -18.8% | $2.7M -34.1% | $4.1M +64.2% | $2.5M +3032.9% | $79.0K | $1.3B | -$1.5B | -$1.6B |
| Interest Expense | $7.0M +196.3% | $2.3M +26.6% | $1.9M +31.4% | $1.4M +21.3% | $1.2M | $969.2M | $1.1B | $1.0B |
| Other Income / Expenses | -$2.3M -201.8% | $2.3M +101.1% | $1.1M +27.9% | $889.0K +176.5% | -$1.2M | -$1.6B | -$1.5B | $1.4B |
| Income Before Tax | -$8.9M +84.0% | -$55.8M +58.8% | -$135.3M +23.0% | -$175.7M -48.9% | -$118.0M | -$15.6B | $3.3B | $4.9B |
| Pre-Tax Margin | -1.9% +11.4pp | -13.3% +24.7pp | -38.0% +24.5pp | -62.5% -7.2pp | -55.3% | 13.3% | 20.8% | 18.7% |
| Income Tax Expense | -$11.2M -514.1% | $2.7M +76.0% | $1.5M +219.5% | $483.0K +165.4% | $182.0K | $666.8M | $1.3B | -$1.6B |
| Net Income | $2.3M +103.9% | -$58.5M +57.2% | -$136.9M +22.3% | -$176.1M -49.1% | -$118.2M | $5.0B | $4.9B | $4.8B |
| Net Margin | 0.5% +14.4pp | -13.9% +24.5pp | -38.4% +24.3pp | -62.7% -7.3pp | -55.4% | 7.4% | 12.4% | 17.5% |
| EPS (Basic) | $0 +103.8% | -$1 +59.4% | -$3 +25.3% | -$3 -41.8% | -$2 | $1.2B | $400.8M | $703.2M |
| EPS (Diluted) | $0 +103.7% | -$1 +59.4% | -$3 +25.3% | -$3 -41.8% | -$2 | $620.6M | $766.2M | $609.4M |
| Weighted Avg Shares | $59.7M +3.7% | $57.6M +5.6% | $54.6M +4.0% | $52.4M +5.1% | $49.9M | $892.2M | $757.8M | $925.8M |
| Weighted Avg Shares (Diluted) | $61.5M +6.8% | $57.6M +5.6% | $54.6M +4.0% | $52.4M +5.1% | $49.9M | $319.6M | $1.2B | $924.4M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Establishment Labs Holdings Inc.
NASDAQ:ESTA
$2.42B
NovoCure Limited
NASDAQ:NVCR
$2.06B
Neogen Corporation
NASDAQ:NEOG
$1.98B
Omnicell, Inc.
NASDAQ:OMCL
$1.72B
Teladoc Health, Inc.
NYSE:TDOC
$1.32B
BioLife Solutions, Inc.
NASDAQ:BLFS
$1.28B
Kestra Medical Technologies, Ltd.
NASDAQ:KMTS
$1.22B
Schrödinger, Inc.
NASDAQ:SDGR
$1.08B
Omada Health
NASDAQ:OMDA
$1.02B
GoodRx Holdings, Inc.
NASDAQ:GDRX
$918.57M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does PHR generate?
Phreesia, Inc. (PHR) reported $480.59M of revenue in fiscal 2026.
Is PHR profitable?
Phreesia, Inc. (PHR) reported $2.31M of net income, with a net margin of 0.5%.
Explore More
Continue the stock analysis
Jump to another research area for this company.